Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta
This article was originally published in The Pink Sheet Daily
Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.
You may also be interested in...
Women’s health is the focus of a two- to five-year research alliance between the German conglomerate and one of Europe’s largest biomedical research centers.
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.